Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
A graphical look at some of the key changes to expect in industry fees and FDA performance commitments based on a draft deal to reauthorize the medical device user fee program (MDUFA VI).
Despite geopolitical challenges and fierce competition for capital, the medtech investment market has maintained the momentum from 2025 through 2026, according to PwC’s latest medtech deals outlook.
FDA proposes a “competency” framework for regulating generative AI; Excerpted from Pathways Picks August 19: FDA GenAI Plan, Commish Nom, Global Picks, and More.